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Major depression disorder (MDD) signiﬁcantly increases the risk for coronary heart disease (CHD) which is a leading cause
of mortality in patients with MDD. Moreover, depression is frequently observed in a subset of patients following acute
coronary syndrome (ACS) and increases risk for mortality. Here evidence implicating omega-3 (n-3) fatty acid deﬁciency in the
pathoaetiologyofCHDandMDDisreviewed,andthehypothesisthatn-3fattyaciddeﬁciencyisapreventableriskfactorforCHD
comorbidity in MDD patients is evaluated. This hypothesis is supported by cross-national and cross-sectional epidemiological
surveys ﬁnding an inverse correlation between n-3 fatty acid status and prevalence rates of both CHD and MDD, prospective
studies ﬁnding that lower dietary or membrane EPA+DHA levels increase risk for both MDD and CHD, case-control studies
ﬁnding that the n-3 fatty acid status of MDD patients places them at high risk for emergent CHD morbidity and mortality,
meta-analyses of controlled n-3 fatty acid intervention studies ﬁnding signiﬁcant advantage over placebo for reducing depression
symptom severity in MDD patients, and for secondary prevention of cardiac events in CHD patients, ﬁndings that n-3 fatty
acid status is inversely correlated with other documented CHD risk factors, and patients diagnosed with MDD after ACS exhibit
signiﬁcantly lower n-3 fatty acid status compared with nondepressed ACS patients. This body of evidence provides strong support
for future studies to evaluate the eﬀects of increasing dietary n-3 fatty acid status on CHD comorbidity and mortality in MDD
patients.
Copyright © 2009 Robert K. McNamara. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
In the year 2000, the World Health Organization (WHO)
identiﬁed major depressive disorder (MDD) as the fourth
ranked cause of disability and premature death globally and
projected that by 2020 MDD and ischemic heart disease will
be the two most important causes of disability worldwide
[1, 2]. These global trends suggest that the prevalence rates
of MDD and coronary heart disease (CHD) are increasing
in parallel, and emerging data suggest a high degree of
symptomatic comorbidity. Speciﬁcally, meta-analyses and
systematic reviews of epidemiological evidence support the
following: (1) clinical depression is an independent risk
factorforthedevelopmentofCHD,(2)severityofdepression
is positively correlated with CHD risk, (3) a subset of
patients with CHD (20–30%) exhibit comorbid depression,
(4) depressive symptoms increase secondary cardiovascular
events and mortality in CHD patients, and (5) CHD is
a leading cause of excessive mortality in MDD patients,
particularly among women [3–9] .T h eh i g hr a t eo fC H D
comorbidity in MDD is therefore suggestive of a common
underlying pathoaetiological mechanism(s).
The pathoaetiology of MDD [10–12] and CHD [13–16]
involves both genetic and environmental factors, and both
genetic and environmental risk factors have been proposed
to account for their comorbidity [17]. A rapidly emerging
body of evidence suggests that membrane omega-3 (n-3)
fatty acid deﬁciency is a preventable risk factor for both
CHD [18]a n dM D D[ 19]. Based on this body of evidence,
a scientiﬁc advisory panel convened by the American
Psychiatric Association (APA) recommended that patients
with aﬀective disorders including MDD increase their daily2 Cardiovascular Psychiatry and Neurology
EPA+DHA intake to 1g/d [20], a daily dose previously
endorsed by the American Heart Association (AHA) [21].
Although this evidence was obtained fromstudies conducted
largely in parallel in the ﬁelds of cardiology and psychiatry,
the potential contribution of n-3 fatty acid deﬁciency to
increased CHD morbidity and mortality in MDD has been
postulated previously [22, 23]. Nevertheless, a large body
of evidence has emerged subsequently that permits a re-
evaluation of this potential interrelationship.
To evaluate the hypothesis that n-3 fatty acid deﬁciency
is a risk factor for CHD morbidity and mortality in MDD, it
is important to consider that the age at onset for unipolar
and bipolar depression peaks in young adulthood (15–19
years) [24, 25], whereas CHD mortality peaks substantially
later (75–84 years) [26]. Therefore, this hypothesis would
additionally posit that cerebral hypoperfusion and depressed
mood [27, 28] are early manifestations of cardiovascular
insuﬃciency associated with n-3 fatty acid deﬁciency [29,
30], and the progressive deterioration of cardiovascular and
cerebrovascular integrity over the lifespan increases risk for
CHD morbidity and mortality in older patients with MDD
[31]. Accordingly, this hypothesis predicts that optimization
of n-3 fatty acid status and associated cardiovascular and
cerebrovascular integrity prior to onset will be an eﬃcacious
preventive strategy for both MDD and CHD.
2.Omega-3 FattyAcidBiosynthesis and
Membrane Accrual
As background, mammals are incapable of synthesizing n-3
fatty acids de novo and are therefore entirely dependent on
dietary sources to procure and maintain adequate concen-
trations in peripheral and central phospholipid membranes.
Dietary sources of the vegetable n-3 fatty acid precursor α-
linolenic acid (ALA, 18:3n-3) include ﬂaxseed, rape, linseed,
canola, soy, and perilla oils. The biosynthesis of eicos-
apentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid
(DHA, 22:6n-3) from ALA requires a series of microsomal
elongation and delta-5 and delta-6 desaturase-mediated
reactions [32, 33], and the ﬁnal synthesis of DHA requires
additional conversions within peroxisomes [34]( Figure 1).
Nevertheless, preformed EPA and DHA can be obtained
directly from the diet, including salmon, sardines, trout,
and tuna, seafood and supplements, thereby bypassing this
biosynthetic pathway. Delta-5 (FADS1) and delta-6 (FADS2)
desaturase genes are colocalized to chromosome 11 (11q12-
1 3 . 1 ) ,a n da r eh i g h l ye x p r e s s e di nl i v e r ,h e a r t ,a n db r a i n
[35–38]. The expression and activities of these enzymes are
regulated by multiple factors including dietary n-3 fatty acid
intake [35, 36, 39], gonadal hormones [40–42], and insulin
[43]. Furthermore, the biosynthesis of n-6 fatty acids from
the dietary precursor linoleic acid (LA, 18:2n-6) utilizes the
sameenzymaticpathwayinacompetitivemanner(Figure 1).
Accordingly, dietary deﬁcits in ALA (18:3n-3) are associated
with a signiﬁcant increase in n-6 fatty acid biosynthesis from
dietary LA [44, 45], and western diets which have a high LA
content are associated with limited (<1.0%) EPA and DHA
biosynthesis from ALA [46–50].
Emerging data also indicate that common single
nucleotide polymorphisms in FADS1 and FADS2 genes are
an important determinant of RBC, plasma, and breast milk
n-3 and n-6 fatty acid composition [51–54]. For example,
a case-control study found that subjects carrying FADS
haplotypes and consuming a Western diet exhibit a higher
index of n-6 fatty acid biosynthesis (arachidonic acid :
LA ratio), and this index was an independent risk factor
for coronary artery disease [55]. Taken collectively, these
ﬁndings indicate that membrane n-3 and n-6 fatty acid
composition is governed by both environmental (dietary n-
6/n-3 fatty acid ratio) and genetic factors.
3. Epidemiology
There are large cross-national variations in per capita
ﬁsh/seafood consumption, a surrogate for EPA+DHA
intake. For example, annual seafood consumption in Japan
(148lb/person) is approximately 3-fold higher than in the
USA (48lb/person) [56] ,a n dt h i si sr e ﬂ e c t e di na∼2-fold
greater red blood cell (RBC) membrane EPA+DHA compo-
sition in Japanese adults (8.5 ± 1.8%) [57] compared with
USAadults(4.9±2.1%)[58].Moreover,therearelargecross-
national variations in the lifetime prevalence rates of MDD
and CHD mortality. For example, life-time prevalence rates
of MDD in Japan (<3%) [59, 60]a r e∼6-fold lower than in
the USA (16.2%) [61], and the prevalence of CHD mortality
among Japanese men aged 55–64 years (58/100000) is 6-
fold lower than among American white men in the USA
(345/100000) [62]. Across multiple countries, there is a
signiﬁcant inverse correlation between per capita ﬁsh or
seafood consumption and the lifetime prevalence rates of
unipolar depression [63, 64], bipolar depression [65], and
postpartumdepression[66].Together,thesedatasuggestthat
cross-national variations in n-3 fatty acid intake are inversely
correlated with the prevalence of MDD and CHD mortality.
However,thepotentialcontributionofothernutrientsfound
in ﬁsh/seafood and other cultural and genetic diﬀerences
preclude deﬁnitive evaluation of their interrelationship.
On a smaller scale, cross-sectional studies have also
observed an inverse relationship between dietary n-3 fatty
acid intake and prevalence rates of MDD, and that this
relationshipisstrongeramongwomen[67–72].Forexample,
the Northern Finland 1966 birth cohort study, a prospective
survey of 2721 males and 2968 females adults (age: 31 years),
found that the risk of developing depression increased 2.6-
fold among females, but not males, who were rare ﬁsh eaters
(monthly) compared with regular (weekly) ﬁsh eaters [72].
Moreover, a cross-sectional survey of 9806 male and 12029
female adult and elderly subjects (40–74 years) from Norway
found that subjects who ingested cod liver oil on a daily
basis (DHA: ∼300–600 mg/d, EPA: ∼300–600 mg/d) were
signiﬁcantly less likely to have depressive symptoms than
nonusers after adjusting for multiple confounding factors
[70]. Similarly, cross-sectional surveys have found an inverse
correlation between dietary n-3 fatty acid intake and CHD
risk factors, nonfatal acute coronary syndrome (ACS), and
sudden cardiac death (SCD) [73, 74]. Lastly, shifting dietsCardiovascular Psychiatry and Neurology 3
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Figure 1: Diagram illustrating the biosynthetic pathway of n-3 and n-6 fatty acids from dietary precursors. The biosynthesis of EPA (20:5n-
3) and DHA (22:6n-3) from dietary α-linolenic acid (18:3n-3), and arachidonic acid (20:4n-6) from linoleic acid (18:2n-6), requires a series
of common and competitive microsomal elongation and delta-5 and delta-6 desaturase-mediated reactions. The ﬁnal synthesis of DHA
requires additional modiﬁcations within peroxisomes. Preformed DHA (22:6n-3), the principle membrane esteriﬁed n-3 fatty acid, and EPA
can be obtained directly from the diet. COX-2 mediated metabolism of DHA and arachidonic acid yields anti-inﬂammatory docosenoids
and proinﬂammatory eicosanoids, respectively. Because the n-6 and n-3 arms compete for common biosynthetic enzymes, elevations in the
dietary LA : ALA ratio increase n-6 fatty acid biosynthesis (reﬂected as reductions in membrane LA and elevations in downstream fatty acid
metabolites) and reduced n-3 fatty acid biosynthesis from ALA (reﬂected as reductions in membrane EPA+DHA).
in Arctic populations away from ﬁsh-based to western diets
have been associated with increased rates of both depression
and CHD [75].
4. ProspectiveLongitudinal
ObservationalStudies
Another approach taken to evaluate the contribution of
n-3 fatty acid status to the pathoaetiology of MDD and
CHD is prospective longitudinal observational studies using
baseline dietary n-3 fatty acid intake or membrane n-3 fatty
acid composition as the predictor variable. In one of the
largest prospective studies conducted to date, EPA+DHA
intake was determined at baseline in 3317 young adult men
and women (mean age: 32 years) residing in the USA, and
depressive symptoms determined at a 10-year follow-up. It
was found that among both men and women, the highest
quartile of EPA+DHA intake at baseline was associated with
a lower adjusted risk for depression at 10 years relative to
the lowest quintile, and this association was stronger in
women [76]. Other studies have evaluated membrane n-3
fatty acid status and the emergence of perinatal depression in
pregnant women. In a recent prospective case-control study
of depressed and nondepressed women, it was found that
higher plasma DHA and total n-3 fatty acid composition
in the third trimester were associated with a signiﬁcantly
lower adjusted risk for depression [77]. In this study, women
with the lowest plasma n-3 fatty acid levels were six times
more likely to be depressed than women who had the
highest n-3 fatty acid levels. Similarly, another study found
that low or no n-3 fatty acids intake from ﬁsh/seafood
were associated with a higher incidence perinatal depression
relative to the highest quartiles of n-3 fatty acids intake
[78]. A third study found that faster recovery of plasma
DHA content postpartum was associated with reduced risk
of postpartum depression [79]. Together, these ﬁndings
provide prospective evidence for an inverse and independent4 Cardiovascular Psychiatry and Neurology
relationship between n-3 fatty acid status and the emergence
of clinical depression.
Several large prospective longitudinal studies have evalu-
ated the relationship between baseline n-3 fatty acid status
and the emergence of CHD mortality. In the Physicians’
Health Study, a prospective case-control study of 14,916
healthy adult male physicians (aged 25–74 years) found
that 94 men experienced sudden cardiac death (SCD) over
the following 17 years. Whole blood long-chain n-3 fatty
acid composition in SCD cases was compared with 184
demographically matched controls. It was found that the
adjusted risk for SCD was reduced by 80% in subjects with
the highest blood n-3 fatty acid levels compared with those
with the lowest levels [80]. In a similar study, 334 adult
(aged 25–74 years) patients with primary cardiac arrest were
compared with 493 control cases and controls free of prior
CHD. It was found that subjects with a red blood cell (RBC)
EPA+DHA composition of 3.3% exhibited a 70% greater
adjusted risk for primary cardiac arrest compared with those
with a RBC EPA+DHA composition of 5.0% [81]. Similarly,
in a cohort of 94 subjects with ACS and 94 age-, gender-, and
race-matchedcontrols,wholebloodEPA+DHAcomposition
in ACS patients was 29% lower than in controls, and the
adjusted odds ratio for ACS was 0.67 [82]. The Nurses’
Health Study, a prospective analysis of 84688 women (aged
34–59 years) without evidence of prior CHD and followed
f o ru pt o1 6y e a r s ,f o u n dt h a tw o m e nw h or a r e l ya t eﬁ s h( <1
per month) had a higher risk of CHD death compared with
women with a higher intake of ﬁsh, with adjusted relative
risks (RR) of 1.0, 0.93, 0.78, 0.68, and 0.67 across intake
quintiles [83]. Lastly, a meta-analysis of 13 cohorts including
222364 subjects followed for a mean of 11.8 years found
that subjects with low or no n-3 fatty acids intake from
ﬁsh/seafood experienced greater CHD mortality compared
with individuals with a higher intake of ﬁsh [84]. The
adjusted RRs for CHD mortality decreased with increasing
ﬁsh intake frequency: 1–3 times per month (RR: 0.89), once
per week (RR: 0.85), 2–4 times per week (RR: 0.77), and
5 or more times per week (RR: 0.62). Each 20g/d increase
in ﬁsh intake was related to a 7% decreased risk of CHD
mortality.
Together, these data indicate that low or no EPA+DHA
intake is an independent risk factor for both CHD and
MDD. However, only one prospective longitudinal study
has evaluated the interrelationship between baseline n-
3 fatty acid intake, baseline depressive symptom severity,
and the emergence of CHD. The Zutphen Elderly Study,
a prospective cohort study conducted in 332 elderly men
(aged 70–90 years) residing in the Netherlands, found that
higher baseline dietary EPA+DHA intake (mean: 407mg/d)
was associated with a 54% lower adjusted risk for mild to
severe depression relative to lower dietary EPA+DHA intake
(mean: 21mg/d). However, baseline dietary EPA+DHA
intake was not associated with a signiﬁcant diﬀerence in the
adjusted risk for CHD mortality during the 10-year follow-
up period [85]. The authors concluded that these data do
not support the hypothesis that lower n-3 fatty acid intake
can account for the relationship between depression and
CHD.
5.Controlledn-3 FattyAcidInterventionTrials
A method used to evaluate the causal relationship between
n-3 fatty acid status and the pathophysiology of MDD and
CHD is double blind randomized placebo-controlled n-
3 fatty acid intervention trials. The results of randomized
controlled n-3 fatty acid intervention trials in patients with
unipolar or bipolar depression have been systematically
reviewed previously [19, 20, 86–90]. Despite small sample
sizes, negative trials, heterogeneity in study design in terms
ofdailyn-3fattyaciddose,typeofn-3fattyacidintervention
(DHA, EPA, EPA+DHA), EPA : DHA ratio, intervention
duration, concomitant medication eﬀects, and depression
symptom severity at baseline, independent meta-analyses
havefoundasigniﬁcantadvantageofn-3fattyacidtreatment
over placebo in patients with clinical depression [20, 86,
87, 90]. Importantly, the majority of patients in these
trials were being administered antidepressant or mood-
stabilizer medications, which may have blunted the eﬀect
size associated with the n-3 fatty acid intervention. For
example, a preliminary randomized, double-blind placebo-
controlled trial found that chronic dietary n-3 fatty acid
(EPA+DHA) monotherapy signiﬁcantly reduced symptom
severity in pediatric and adolescent (8–12 years) patients
withMDD[91]. Independent meta-analyses have also found
a signiﬁcant advantage of n-3 fatty acid treatment over
placebo or usual care for event-free survival in patients
with established CHD [92, 93]. In one of the largest studies
conducted to date, the Japan EPA Lipid Intervention Study
found that the risk for nonfatal major cardiac events in
a cohort of 18645 hypercolecterolemic men and women
with or without a history of CHD was reduced by 19
percent in patients treated with EPA plus statin compared
with statin alone [94]. Together, these secondary prevention
studies provide evidence that depression symptom severity
and CHD risk are both signiﬁcantly attenuated by increasing
n-3 fatty acid status. To date, however, there have been no
controlled n-3 fatty acid primary prevention (monotherapy)
trials conducted in subjects at risk for CHD or MDD, nor
have there been primary prevention trials evaluating cardiac
outcomes in MDD patients.
6. Membrane n-3 FattyAcid
Composition Studies
Case-control studies have compared the n-3 fatty acid status
of patients with demographically similar healthy controls
using plasma, RBC, and adipose n-3 fatty acid composition.
Importantly, RBC membrane EPA+DHA composition is
highly correlated with habitual dietary EPA+DHA intake
and plasma phospholipid EPA+DHA composition [95, 96].
Moreover, RBC membrane EPA+DHA composition is highly
correlated human myocardium biopsy EPA+DHA compo-
sition [97] and primate frontal gray matter biopsy DHA
composition [98]. Based on prior prospective longitudinal
data reviewed above, RBC EPA+DHA composition (termed
the “omega-3 index”) has been proposed as a novel risk
biomarker for CHD mortality, and risk zones have beenCardiovascular Psychiatry and Neurology 5
Table 1: Omega-3 index in patients with MDD.
Study Country Blood fraction Sample size (case : control) Omega-3 index1 (case : control) Δ
Maes et al. [103] Belgium Plasma 36 : 24 3.6:3 .8 −5%
Maes et al. [104] Belgium Plasma 34 : 14 4.5:4 .9 −7%
Tiemeier et al. [107] Netherlands Plasma 106 : 461 4.4:4 .6 −4%
Peet et al. [106]U . K . R B C 1 5 : 1 5 3 .6:6 .3 −42%
Edwards et al. [102]U . K . R B C 1 4 : 1 0 3 .8:5 .4 −31%
McNamara et al. [105]U . S . R B C 1 7 : 2 0 3 .8:4 .8 −21%
Total — — 218 : 548 3.9:5 .0 −21%
 = Mean percent diﬀerence from controls
1Mean EPA+DHA wt % total fatty acid composition.
deﬁned [99]. Speciﬁcally, RBC EPA+DHA composition of
<4% is high risk, 4%–8% is intermediate risk, and >8% is
low risk. An “omega-3 index” of ≤4% is associated with a
10-fold greater risk for SCD compared to an omega-3 index
of >8% [99]. Additionally, RBC EPA+DHA composition is
signiﬁcantly lower in patients with acute coronary syndrome
(ACS) compared with age-, sex-, and race-matched controls
[100], and a meta-analysis of prospective studies found that
RBC DHA composition was inversely correlated with CHD
events [101].
In the last 20 years there have been at least 6 published
case-control studies from developed western countries that
have compared peripheral (plasma, RBC) n-3 fatty acid
composition in MDD patients and healthy controls. In all of
these studies, signiﬁcantly lower plasma or RBC EPA+DHA
composition was observed in MDD patients relative to
healthy controls [102–107]( Table 1). In a small case-control
study conducted in the USA, we recently found that young
adult MDD patients (n = 17, mean age: 35 years) exhibited
RBC EPA+DHA composition that was signiﬁcantly lower
than healthy adult controls (n = 20, mean age: 35 years)
(3.8% ± 1.0% versus 4.8 ± 1.1%, P = .006) [105]. In this
cohort, 65% of MDD patients exhibited an RBC EPA+DHA
index of ≤4.0% compared with 25% of controls. Analysis of
combined case-control studies indicates that MDD patients
(n = 548) exhibit RBC or plasma EPA+DHA values that are
21%lowerthanhealthycontrols(n = 218)(3.9±0.4%versus
5.0 ±0.8%, P = .01) (Table 1). These ﬁndings are signiﬁcant
because they suggest that patients with MDD exhibit an RBC
EPA+DHA index that is similar to that observed in patients
with ACS (3.4 ± 1.6%) [100]a n d ,b a s e do np r o s p e c t i v e
observational studies, suggests that at least a subset of MDD
patients are in the high-risk (≤4.0%) category for SCD [99].
Speciﬁcally, these data suggest that MDD patients have a
∼60% greater risk for primary cardiac arrest compared with
healthy controls [81] and a 10-fold greater risk for SCD
compared to adult Japanese subjects (Figure 2).
To date there have been three studies that have deter-
mined the interrelationship between n-3 fatty acid status
and depression in patients with established CHD. In the
ﬁrst study, ACS patients diagnosed with MDD exhibited
signiﬁcantly lower plasma EPA+DHA levels compared with
nondepressed ACS patients [108]. In a second study, ACS
patients with current depression had signiﬁcantly lower
mean plasma total n-3 fatty acid and DHA compared with
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Figure 2: Comparison of the “omega-3 index” (RBC EPA+DHA
composition) in adult USA patients with acute coronary syndrome
(ACS, n = 768) [100], adult MDD patients residing in the USA
or UK (n = 42) [102, 105, 106], healthy adults (HAs) residing
in the U.S. (n = 163) [58], and healthy adults residing in Japan
(n = 456)[57].Proposedriskzonesforsuddencardiacdeath(SCD)
derived from prior prospective longitudinal evidence are indicated
[99]. Note that MDD patients exhibit an “omega-3 index” that is
similar to patients with ACS and places them at high risk for SCD.
those without current depression, and depression symptom
severity was inversely correlated with plasma DHA compo-
sition [109]. In a third larger study, among ACS patients
(n = 759), those with depression exhibited signiﬁcantly
lower RBC EPA+DHA composition relative to those without
depression (2.9 ± 1.5% versus 3.3 ± 1.8%, P = .002)
[110]. Taken collectively, these data support an inverse
relationship between n-3 fatty acid status and depression in
ACS patients.
7.Biological Mechanisms
There are several plausible biological mechanisms that could
potentially link membrane n-3 fatty acid deﬁciency observed
in MDD with increased risk for CHD. In addition to
emerging clinical and preclinical evidence that n-3 fatty
acids are protective against cardiac arrhythmias [111–114],
other mechanisms including enhanced platelet reactivity and
aggregation, elevated triglyceride levels, and inﬂammation,
have received increasing experimental attention and are
reviewed separately below.6 Cardiovascular Psychiatry and Neurology
7.1. Platelet Aggregation. The antithrombotic actions of n-
3 fatty acids have been well documented [115], and platelet
functional abnormalities, including increased platelet reac-
tivity and aggregation associated with thromboembolic
events, have been proposed as a potential mechanism by
which depression increases risk for CHD [116, 117]. Blood
platelets express serotonin 5-HT2A receptors, and elevated 5-
HT2A receptorbindingdensityhasbeenobservedinplatelets,
as well as postmortem prefrontal cortex, of depressed suicide
victims [118–122]. Moreover, chronic dietary n-3 fatty acid
insuﬃciency is associated with signiﬁcant elevations in 5-
HT2A receptor binding density in the rat prefrontal cortex
[123, 124]. Platelet 5-HT2A receptors are coupled to the
phosphoinositide (PI) signal transduction pathway, and
platelets obtained from MDD patients exhibit several indices
consistentwithPI-signalinghyperactivity,includingelevated
basal and/or stimulated intracellular inositol triphosphate,
diacylglycerol, and/or calcium concentrations [125]. It is rel-
evant, therefore, that previous preclinical studies have found
that chronic EPA+DHA feeding signiﬁcantly reduces indices
of basal and stimulated PI signal transduction in platelets,
neutrophils, and cardiac myocytes [126–129]. Moreover,
5-HT2A receptors may also be coupled to phospholipase
A2 (PLA2) which liberates membrane acetylated arachi-
donic acid, a precursor for proinﬂammatory prostaglandin
synthesis, and chronic dietary n-3 fatty acid deﬁciency is
associated with signiﬁcant elevations in PLA2 activity in
the rat prefrontal cortex [130]. Together, these data suggest
that elevated platelet 5-HT2A receptor-mediated signaling
secondary to n-3 fatty acid deﬁciency may increase risk of
thromboembolic events in patients with MDD and CHD
[131].
7.2. Inﬂammation. The mechanisms by which EPA+DHA
reduce inﬂammatory signaling have been reviewed in
detail previously [132] and include direct competition
for cyclooxygenase-2- (COX-2) mediated arachidonic acid
metabolism into proinﬂammatory prostaglandins and sup-
pression of proinﬂammatory cytokine production. Several
cross-sectional studies have observed an inverse correlation
between blood EPA+DHA levels and markers of inﬂam-
mation, including C-reactive protein (CRP) and proinﬂam-
matory cytokine interleukin-6 (IL-6) levels, among healthy
adult men and women [133–136]. Inﬂammation is thought
to be a key factor in the progression of atherosclerotic
vascular disease, and elevations in the inﬂammatory marker
CRP are associated with higher long-term risk for future
CHD events [137]. Moreover, a cross-sectional study of
992 individuals with stable coronary artery disease found
that RBC DHA+EPA levels were inversely and indepen-
dently correlated with CRP and IL-6 levels [138], and a
randomized controlled study found that chronic (91 d)
DHA treatment signiﬁcantly reduced CRP and IL-6 levels
in hypertriglyceridemic men [139]. Cross-sectional surveys
a n dc a s e - c o n t r o ls t u d i e sh a v ea l s of o u n de l e v a t e db l o o d
markers of inﬂammation, including CRP and IL-6, in
patients with MDD relative to healthy controls, and that
these markers were positively correlated with depression
symptom severity [140–145]. Lastly, greater CRP levels have
been observed in CHD outpatients with MDD compared
with CHD outpatients without MDD [146]. However, it is
notable that the Heart and Soul Study of 984 participants
found that current MDD was associated with lower levels
of inﬂammatory marker including CRP and IL-6 in both
unadjusted and adjusted models [147].
7.3. Elevated Triglycerides. Elevated triglyceride levels (200–
500mg/dL) have been found to be an independent, albeit
modest, risk factor for CHD [148–150]. It has been known
for over 20 years that the regular consumption of ﬁsh is
associated with a 20%–40% reduction in plasma triglyceride
levels [151], and n-3 fatty acids decrease hepatic triglyceride
biosynthesis and hepatic clearance [152]. Several random-
ized controlled trials have consistently observed signiﬁcant
reductions in triglyceride levels (∼25%) following daily
EPA+DHA (∼4g/d) treatment relative to placebo in patients
with hypertriglyceridemia (≥500mg/dL) [153]. It is also
notable that a study reported reduced depression symptom
severity following resolution of severe hypertriglyceridemia
(≥500mg/dl) after treatment with gemﬁbrozil (Lopid)
[154]. The American Heart Association currently recom-
mends that patients with hypertriglyceridemia consume
2–4g EPA+DHA per day [155], and in 2004 the U.S.
Food and Drug Administration approved EPA+DHA ethyl
esters (Omacor) for adjunctive treatment of hypertrigyc-
eridemia. Moreover, two randomized controlled trials found
that concomitant treatment with EPA [156] or EPA+DHA
[157] signiﬁcantly and dose-dependently decreased elevated
triglyceride levels in schizophrenic patients treated with the
atypical antipsychotic clozapine.
Surprisingly few studies have investigated fasting triglyc-
eridelevelsinpatients withMDD,andtheexisting resultsare
mixed. For example, one small case-control study found that
although fasting triglyceride levels in male and female MDD
patients did not diﬀer from healthy controls, triglyceride
levels were greater in male patients with melancholic features
compared with men with atypical features [158]. A second
case-control study that did not segregate by MDD subtype
did not observe signiﬁcant diﬀerences in fasting triglyceride
levels in MDD patients (n = 100) relative to healthy
controls (n = 100) [159]. Moreover, a cross-sectional
study of 3490 men aged 31–45 years did not observe
elevatedtriglyceridesinsubjectsdiagnosedwithMDD[160],
and another study found that triglyceride levels were not
associatedwithdepression1monthafteranacutemyocardial
infarction [161]. However, a cross-sectional study found
that in a sample of 5439 men aged 71–89 years, 32% of
subjects with depression had high fasting triglyceride levels
compared with 21% of nondepressed subjects [162], and
patients diagnosed with MDD after a recent ACS exhibited
signiﬁcantly higher fasting triglyceride levels relative to
nondepressed ACS patients [108]. Although these ﬁndings
do not unanimously support elevated triglyceride levels
in MDD, recent studies have found a stronger association
between nonfasting (postprandial state) triglyceride levels
and cardiovascular risk compared to fasting triglycerideCardiovascular Psychiatry and Neurology 7
levels [163, 164]. Moreover, elevated triglyceride levels
(>150mg/dL) are observed in 25%–35% of the general U.S.
population [165]. Future studies are therefore warranted
to investigate whether patients with MDD exhibit elevated
nonfasting triglyceride levels, and whether these levels are
associatedwithn-3fattyacidstatusanddepressionsymptom
severity.
8. Conclusions andHypothesis Evaluation
There is now a substantial body of evidence linking n-3
fatty acid deﬁciency with both MDD and CHD. Support
for the hypothesis that n-3 fatty acid deﬁciency represents
a preventable risk factor for comorbid CHD in MDD
includes (1) cross-national and cross-sectional epidemiolog-
ical surveys ﬁnding an inverse correlation between n-3 fatty
acid status and prevalence rates of both CHD and MDD,
(2) prospective studies ﬁnding that lower dietary or RBC
EPA+DHA levels increase risk for both MDD and CHD,
(3) case-control studies ﬁnding that a large subset of MDD
patients exhibit an RBC EPA+DHA level that places them
at high risk for emergent CHD morbidity and mortality
relative to the general population, (4) meta-analyses of
randomized controlled secondary n-3 fatty acid intervention
studies ﬁnding signiﬁcant advantage of n-3 fatty acids over
placebo for secondary prevention of cardiac events in CHD
patients and depression symptom severity in MDD patients,
(5) cross-sectional and controlled intervention studies ﬁnd-
ing that n-3 fatty acid status is inversely correlated with
other documented CHD risk factors, including increased
platelet reactivity and aggregation, augmented inﬂammatory
signaling,andelevatedfastingtriglyceridelevels,and(6)ACS
patients diagnosed with MDD exhibit signiﬁcantly lower
plasma EPA+DHA levels compared with nondepressed ACS
patients.
The most direct refutation of this hypothesis comes from
a prospective longitudinal study ﬁnding that baseline n-
3 fatty acid intake was inversely correlated with baseline
depressive symptoms but was not associated with increased
long-term CHD risk [85]. However, this study has several
notable limitations. Firstly, this study did not account for
potential changes in dietary n-3 fatty acid intake after base-
line measurements were obtained, and it remains possible
that subjects increased n-3 fatty acid intake postbaseline.
Second, this study was conducted in a relatively small cohort
(n = 332), and larger prospective trials have observed an
inverse relationship between baseline n-3 fatty acid status
and long-term CHD risk (reviewed above). Lastly, this
study used a dietary n-3 fatty acid questionnaire to deﬁne
baseline n-3 fatty acid status, and no objective measures (i.e.,
RBC EPA+DHA composition) were collected to corroborate
accuracy.
In view of the weight of current evidence, additional
studies are clearly warranted to directly evaluate the inter-
relationship between n-3 fatty acid deﬁciency and CHD
comorbidity in MDD. A deﬁnitive test of the proposed
hypothesis would be to determine in a prospective lon-
gitudinal controlled trial whether increasing the n-3 fatty
acid status of MDD patients decreases indices of CHD
risk and emergent cardiac events and mortality. Increasing
RBC EPA+DHA composition to ≥8%, which is associated
with the greatest protection from CHD mortality [99],
would represent an appropriate target, and a prior study
demonstrated that RBC DHA+EPA composition of 7.8%
was achievable after 8-week treatment with DHA (864mg/d)
+ EPA (1,296mg/d) (∼2.0g/d) in adult male and female
subjects [166]. Older MDD patients at greater risk for CHD
mortality at study entry (i.e., RBC EPA+DHA ≥4.0%) would
represent an appropriate cohort. Based on the evidence
reviewed here, it is predicted that increasing n-3 fatty
acid status of MDD patients to ≥8% would be associated
with a signiﬁcant reduction in CHD risk factors, including
depression symptom severity, nonfasting triglyceride levels,
indices of platelet aggregation, CRP and IL-6 levels, and
ultimately reduced risk for emergent cardiac events and
SCD.
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